The world of cancer therapy need not wait for Bologna results, and it will not wait. K moving forward on many fronts simply awaits dosing decisions- so difficult because so far so well tolerated. Once there have been some more regimens for dosing, then we will see things unfold- BIDMC starts moving with sunitinib for renal cancer, then who knows what else. That is why I have been perseverating about preclinical studies for other tumors. Show the world what K looks like with mouse graft tumors for ovarian ca with cisplat, or how it looks for pancreatic CA with gemcitabine, or for small cell lung ca, or melanoma, or glioblastoma plus whatever other agent and let's get on board.
They have said there is efficacy with sunitinib for renal cell ca- I have never seen the data. Let's see some more data and start to line up K plus x and y and z...as long as it has some benefits.
News 
Market Data 
Discover 
AI
